Table 2 Prognostic factors for overall survival of patients with invasive micropapillary breast cancer

Age

 ≤ 50

1.000

 51–64

0.515–1.193

0.899

0.585–1.382

0.628

 ≥ 65

1.327–2.805

2.494

1.657–3.752

< 0.001

Race

 White

–

–

–

 African American

0.667–1.503

–

–

–

 Other

0.277–1.257

–

–

–

Sex

 Female

–

–

–

 Male

0.465–2.740

–

–

–

Charlson–Deyo comorbidity score

 0

1.000

 1

1.311–2.671

1.513

1.049–2.183

0.027

 ≥ 2

1.898–5.910

2.200

1.217–3.978

0.009

Clinical T stage

 1

1.000

 2

1.507–2.794

1.888

1.340–2.660

< 0.001

 3

1.504–3.656

2.230

1.314–3.784

0.003

 4

2.222–5.993

2.851

1.602–5.073

< 0.001

Clinical N stage

 0

1.000

 1

1.122–2.130

1.194

0.771–1.850

0.426

 2

2.390–6.147

2.009

1.099–3.676

0.024

 3

0.852–3.908

0.925

0.292–2.184

0.859

Surgery

 Lumpectomy

1.000

 Mastectomy

1.040–1.812

1.027

0.751–1.404

0.869

Radiotherapy

 Yes

1.000

 No

1.336–2.307

2.344

1.711–3.210

< 0.001

Histologic grade

 Well differentiated

–

–

–

 Moderately differentiated

0.558–1.723

–

–

–

 Poorly differentiated/undifferentiated

0.831–2.552

–

–

–

 Not reported

0.291–1.788

–

–

–

ER status

 Positive

1.000

 Negative

1.629–3.113

2.804

1.827–4.305

< 0.001

 Unknown

0.260–1.906

0.585

0.211–1.626

0.304

PR status

 Positive

1.000

 Negative

1.223–2.227

1.586

1.166–2.156

0.003

 Unknown

0.298–1.788

0.825

0.335–2.045

0.677

HER2 status

 Positive

–

–

–

 Negative

0.604–1.728

–

–

–

 Unknown

0.503–1.460

–

–

–

Chemotherapy

 Yes

–

–

–

 No

0.679–1.230

–

–

–

 Not reported

0.874–1.977

–

–

–

Hormonal therapy

 Yes

1.000

 No

1.134–2.054

0.789

0.538–1.158

0.227

 Not reported

0.745–0.254

1.013

0.567–1.810

0.965

Lymph nodes involved

 0

1.000

 1–3

0.656–1.438

1.087

0.700–1.687

0.711

 4 or more

1.750–3.398

2.292

1.413–3.719

0.001

 Unknown

1.174–0.828

1.507

0.962–2.361

0.073